Laser flare photometry in eyes receiving brolucizumab intravitreal injections for age related macular degeneration.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

European Journal of Ophthalmology Pub Date : 2024-11-01 Epub Date: 2024-03-06 DOI:10.1177/11206721241236917

Nikolaos Chadoulos, Anna Dastiridou, Andreas Mitsios, Ioannis Tsinopoulos, Christos Kalogeropoulos, Sofia Androudi

{"title":"Laser flare photometry in eyes receiving brolucizumab intravitreal injections for age related macular degeneration.","authors":"Nikolaos Chadoulos, Anna Dastiridou, Andreas Mitsios, Ioannis Tsinopoulos, Christos Kalogeropoulos, Sofia Androudi","doi":"10.1177/11206721241236917","DOIUrl":null,"url":null,"abstract":"Purpose: To measure aqueous flare levels in treatment naïve eyes suffering from wet age- related macular degeneration (wAMD) treated with intravitreal brolucizumab.Methods: Patients with treatment naïve wAMD in one eye were prospectively enrolled. Flare levels were measured with laser flare photometry at baseline, 1 day and 1 month after each of the 3 monthly injections during the loading phase.Results: Twenty-two eyes from 22 patients aged 76.7 ± 6.0 years were enrolled. Flare values were 10.6 ± 3.7 photons/msec at baseline and 12.6 ± 5.8 photons/msec at the last follow up visit, 1 month after the third injection (p = 0.289, repeated measures ANOVA). The mean change in flare after the first injection was 4.2 ± 3.6. photons/msec, 6.6 ± 8.9 photons/msec after the 2nd and 8.6 ± 20.8 photons/msec after the 3rd injection (p = 0.640, repeated measures ANOVA). No patient had clinical signs of intraocular inflammation.Conclusions: Eyes receiving brolucizumab injections for wAMD showed similar flare at baseline, during and 1 month after completion of three-monthly intravitreal injections. There was no evidence of subclinical inflammation during the loading phase of brolucizumab based on laser flare photometry measurements.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241236917","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To measure aqueous flare levels in treatment naïve eyes suffering from wet age- related macular degeneration (wAMD) treated with intravitreal brolucizumab.

Methods: Patients with treatment naïve wAMD in one eye were prospectively enrolled. Flare levels were measured with laser flare photometry at baseline, 1 day and 1 month after each of the 3 monthly injections during the loading phase.

Results: Twenty-two eyes from 22 patients aged 76.7 ± 6.0 years were enrolled. Flare values were 10.6 ± 3.7 photons/msec at baseline and 12.6 ± 5.8 photons/msec at the last follow up visit, 1 month after the third injection (p = 0.289, repeated measures ANOVA). The mean change in flare after the first injection was 4.2 ± 3.6. photons/msec, 6.6 ± 8.9 photons/msec after the 2nd and 8.6 ± 20.8 photons/msec after the 3rd injection (p = 0.640, repeated measures ANOVA). No patient had clinical signs of intraocular inflammation.

Conclusions: Eyes receiving brolucizumab injections for wAMD showed similar flare at baseline, during and 1 month after completion of three-monthly intravitreal injections. There was no evidence of subclinical inflammation during the loading phase of brolucizumab based on laser flare photometry measurements.

查看原文本刊更多论文

接受布鲁珠单抗玻璃体内注射治疗老年性黄斑变性的眼睛的激光耀斑光度测量。

目的：测量使用玻璃体内brolucizumab治疗湿性年龄相关性黄斑变性（wAMD）的治疗新患者眼部的水肿水平：方法：前瞻性地招募了单眼湿性年龄相关性黄斑变性（wAMD）治疗新患者。在基线期、负荷期每月注射 3 次后的 1 天和 1 个月，分别用激光耀斑光度计测量耀斑水平：结果：22 名患者的 22 只眼睛入选，年龄为 76.7 ± 6.0 岁。基线耀斑值为 10.6 ± 3.7 光子/毫秒，第三次注射后 1 个月最后一次随访时为 12.6 ± 5.8 光子/毫秒（重复测量方差分析，P = 0.289）。第一次注射后耀斑的平均变化为 4.2 ± 3.6 光子/毫秒，第二次注射后为 6.6 ± 8.9 光子/毫秒，第三次注射后为 8.6 ± 20.8 光子/毫秒（p = 0.640，重复测量方差分析）。没有患者出现眼内炎症的临床症状：结论：接受brolucizumab注射治疗wAMD的眼球在基线、三个月一次的玻璃体内注射期间和完成注射后1个月都出现了相似的耀斑。根据激光耀斑光度测量结果，没有证据表明在注射博卢单抗的负荷阶段存在亚临床炎症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.